A Phase 1/2 Study of AZD6244 in Combination With Sorafenib in Advanced Hepatocellular Carcinoma

Trial Profile

A Phase 1/2 Study of AZD6244 in Combination With Sorafenib in Advanced Hepatocellular Carcinoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Selumetinib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2016 Results from phase Ib part of this study (n=27) published in the Annals of Oncology.
    • 15 Apr 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov. record.
    • 07 Nov 2012 Planned number of patients changed from 100 to 166 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top